Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo

Sonja Von Aulock, Corinna Hermann, Thomas Hartung

Research output: Contribution to journalArticle

Abstract

Recognition of pathogens by immune cells initiates the release of numerous signaling molecules, including cytokines and eicosanoids. Here, we describe a simple procedure by which eicosanoids such as prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and thromboxane B2 (TxB2) can be measured using commercial enzyme immunoassays (EIAs) in the supernatant of whole blood stimulated with inflammatory stimuli. This is illustrated for numerous stimuli. The kinetics by which lipopolysaccharide (LPS) induces cyclooxygenase (COX)-2 expression in this setup were determined by quantitative reverse transcription polymerase chain reaction (RT-PCR). The eicosanoid response of the blood of 160 healthy volunteers to 1 μg/ml LPS was measured. To determine whether the action of a drug in vivo is represented ex vivo in the eicosanoid response of blood, one volunteer took a standard dose of a number of commercially available cyclooxygenase inhibitors on different days and the eicosanoid response of his blood to LPS was determined before ingestion as well as 2 and 6 h afterwards. The efficacy of the different pharmaceuticals on cyclooxygenase but not lipoxygenase products or cytokines could be monitored ex vivo. Similarly, ex vivo eicosanoid release was measured in blood from 10 volunteers who had taken 50 mg flurbiprofen. The method described extends approaches for studying whole blood cytokine release to the lipid mediators formed from arachidonic acid. These important signaling molecules represent targets for pharmacological intervention, which can now be monitored in vitro, as well as ex vivo employing the same model. Furthermore, the assay could be used to characterize the immune status of patient groups or to monitor the course of disease.

Original languageEnglish (US)
Pages (from-to)53-63
Number of pages11
JournalJournal of Immunological Methods
Volume277
Issue number1-2
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Eicosanoids
Pharmacology
Lipopolysaccharides
Cytokines
Volunteers
Flurbiprofen
Thromboxane B2
Leukotriene B4
Lipoxygenase
Cyclooxygenase Inhibitors
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Immunoenzyme Techniques
Dinoprostone
Arachidonic Acid
Pharmaceutical Preparations
Reverse Transcription
Healthy Volunteers
Eating
Lipids

Keywords

  • Eicosanoids
  • Human
  • Lipopolysaccharide
  • Whole blood

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo. / Von Aulock, Sonja; Hermann, Corinna; Hartung, Thomas.

In: Journal of Immunological Methods, Vol. 277, No. 1-2, 01.06.2003, p. 53-63.

Research output: Contribution to journalArticle

@article{44828f54823a4abf92587e3f68a21a93,
title = "Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo",
abstract = "Recognition of pathogens by immune cells initiates the release of numerous signaling molecules, including cytokines and eicosanoids. Here, we describe a simple procedure by which eicosanoids such as prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and thromboxane B2 (TxB2) can be measured using commercial enzyme immunoassays (EIAs) in the supernatant of whole blood stimulated with inflammatory stimuli. This is illustrated for numerous stimuli. The kinetics by which lipopolysaccharide (LPS) induces cyclooxygenase (COX)-2 expression in this setup were determined by quantitative reverse transcription polymerase chain reaction (RT-PCR). The eicosanoid response of the blood of 160 healthy volunteers to 1 μg/ml LPS was measured. To determine whether the action of a drug in vivo is represented ex vivo in the eicosanoid response of blood, one volunteer took a standard dose of a number of commercially available cyclooxygenase inhibitors on different days and the eicosanoid response of his blood to LPS was determined before ingestion as well as 2 and 6 h afterwards. The efficacy of the different pharmaceuticals on cyclooxygenase but not lipoxygenase products or cytokines could be monitored ex vivo. Similarly, ex vivo eicosanoid release was measured in blood from 10 volunteers who had taken 50 mg flurbiprofen. The method described extends approaches for studying whole blood cytokine release to the lipid mediators formed from arachidonic acid. These important signaling molecules represent targets for pharmacological intervention, which can now be monitored in vitro, as well as ex vivo employing the same model. Furthermore, the assay could be used to characterize the immune status of patient groups or to monitor the course of disease.",
keywords = "Eicosanoids, Human, Lipopolysaccharide, Whole blood",
author = "{Von Aulock}, Sonja and Corinna Hermann and Thomas Hartung",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0022-1759(03)00180-7",
language = "English (US)",
volume = "277",
pages = "53--63",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo

AU - Von Aulock, Sonja

AU - Hermann, Corinna

AU - Hartung, Thomas

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Recognition of pathogens by immune cells initiates the release of numerous signaling molecules, including cytokines and eicosanoids. Here, we describe a simple procedure by which eicosanoids such as prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and thromboxane B2 (TxB2) can be measured using commercial enzyme immunoassays (EIAs) in the supernatant of whole blood stimulated with inflammatory stimuli. This is illustrated for numerous stimuli. The kinetics by which lipopolysaccharide (LPS) induces cyclooxygenase (COX)-2 expression in this setup were determined by quantitative reverse transcription polymerase chain reaction (RT-PCR). The eicosanoid response of the blood of 160 healthy volunteers to 1 μg/ml LPS was measured. To determine whether the action of a drug in vivo is represented ex vivo in the eicosanoid response of blood, one volunteer took a standard dose of a number of commercially available cyclooxygenase inhibitors on different days and the eicosanoid response of his blood to LPS was determined before ingestion as well as 2 and 6 h afterwards. The efficacy of the different pharmaceuticals on cyclooxygenase but not lipoxygenase products or cytokines could be monitored ex vivo. Similarly, ex vivo eicosanoid release was measured in blood from 10 volunteers who had taken 50 mg flurbiprofen. The method described extends approaches for studying whole blood cytokine release to the lipid mediators formed from arachidonic acid. These important signaling molecules represent targets for pharmacological intervention, which can now be monitored in vitro, as well as ex vivo employing the same model. Furthermore, the assay could be used to characterize the immune status of patient groups or to monitor the course of disease.

AB - Recognition of pathogens by immune cells initiates the release of numerous signaling molecules, including cytokines and eicosanoids. Here, we describe a simple procedure by which eicosanoids such as prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and thromboxane B2 (TxB2) can be measured using commercial enzyme immunoassays (EIAs) in the supernatant of whole blood stimulated with inflammatory stimuli. This is illustrated for numerous stimuli. The kinetics by which lipopolysaccharide (LPS) induces cyclooxygenase (COX)-2 expression in this setup were determined by quantitative reverse transcription polymerase chain reaction (RT-PCR). The eicosanoid response of the blood of 160 healthy volunteers to 1 μg/ml LPS was measured. To determine whether the action of a drug in vivo is represented ex vivo in the eicosanoid response of blood, one volunteer took a standard dose of a number of commercially available cyclooxygenase inhibitors on different days and the eicosanoid response of his blood to LPS was determined before ingestion as well as 2 and 6 h afterwards. The efficacy of the different pharmaceuticals on cyclooxygenase but not lipoxygenase products or cytokines could be monitored ex vivo. Similarly, ex vivo eicosanoid release was measured in blood from 10 volunteers who had taken 50 mg flurbiprofen. The method described extends approaches for studying whole blood cytokine release to the lipid mediators formed from arachidonic acid. These important signaling molecules represent targets for pharmacological intervention, which can now be monitored in vitro, as well as ex vivo employing the same model. Furthermore, the assay could be used to characterize the immune status of patient groups or to monitor the course of disease.

KW - Eicosanoids

KW - Human

KW - Lipopolysaccharide

KW - Whole blood

UR - http://www.scopus.com/inward/record.url?scp=0038546897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038546897&partnerID=8YFLogxK

U2 - 10.1016/S0022-1759(03)00180-7

DO - 10.1016/S0022-1759(03)00180-7

M3 - Article

C2 - 12799039

AN - SCOPUS:0038546897

VL - 277

SP - 53

EP - 63

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1-2

ER -